Application of PARP1-Specific Pt(II)-Based Targeted Drug Conjugate in the Treatment of Ovarian Cancer by Inhibiting PARP1 and Suppressing DNA Damage Repair
demonstrated higher tumor growth inhibitory efficacy than cisplatin, olaparib, and their physical mixture in SKOV3 mice xenograft models, while exhibiting lower toxicity. Overall, the TDC entity sets a new benchmark for precision therapy in ovarian cancer.
Authors
- Zichen Xu (ORCID: https://orcid.org/0000-0002-6469-7869)
- Shaohua Gou (ORCID: https://orcid.org/0000-0003-0284-5480)
- Heng Zhang (ORCID: https://orcid.org/0009-0004-9095-2618)
Institutions
- Chemical Synthesis Lab (SG)
Publication Details
- Journal
- Inorganic Chemistry
- Published
- 2026-04-17
- DOI
- https://doi.org/10.1021/acs.inorgchem.6c00964
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China